Neurocrine Biosciences Provides Update on ERUDITE™Phase 2 Data For Luvadaxistat
Portfolio Pulse from Benzinga Newsdesk
Neurocrine Biosciences announced that their Phase 2 study for Luvadaxistat did not meet its primary endpoint for treating cognitive impairment in schizophrenia. The company will now focus on Phase 3 development of other drugs for schizophrenia and major depressive disorder.
September 12, 2024 | 8:11 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Neurocrine Biosciences' Phase 2 study for Luvadaxistat failed to meet its primary endpoint, leading the company to shift focus to other drug developments. This could impact investor confidence and short-term stock performance.
The failure to meet the primary endpoint in a Phase 2 study is a significant setback for Neurocrine Biosciences, as it may affect investor confidence and lead to a negative short-term impact on the stock price. The company's decision to focus on other drug developments indicates a strategic shift, but the immediate reaction is likely to be negative.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100